April 11, 2024

CHAIN Biotechnology Ltd and the German Cancer Research Center (DKFZ) have signed an agreement to collaborate on the development of therapeutic cancer vaccines for indications caused by Human Papillomavirus (HPV). The 15-month program focuses on combining the expertise and knowledge of both parties to design and test the anti-tumour efficacy of CHAIN’s novel, orally administered […]

December 19, 2023

Dr Zahid Bashir joins CHAIN Biotechnology’s Board as the new Non-Executive Director (NED) bringing extensive oncology expertise to CHAIN’s pipeline. CHAIN recently reports its expansion into the immune-oncology field, using its proprietary technology to develop immuno-therapeutic candidates with the potential to enhance the efficacy of anti-cancer agents such as Immune Checkpoint Inhibitors (ICIs). This programme […]

July 26, 2023

CHAIN have closed a financing round led by new investors, BGF and SynBioVen, alongside existing investor, UKI2S and strategic partner, Miyarisan Pharmaceutical. Investment will enable CHAIN to develop its CADD therapeutic platform and demonstrate its unique potential for use as an immune therapy in oncology. CHAIN will initially focus on immune therapies to treat Cervical, […]

January 3, 2023

The UK biotech has announced an investment agreement with Japan-based pharmaceutical company Miyarisan to help scale and manufacture their oral therapeutics pipeline. Nottingham, UK- 3rd January 2023- FOR IMMEDIATE RELEASE Miyarisan currently manufacture the probiotic bacterial strain MIYARI 588 for Asian and European markets, and bring extensive Clostridium bacterial spore manufacturing and formulation expertise, along […]

July 22, 2022

CHAIN announces the appointment of Dr Matthew Duchars as Chief Executive from the 1st of August 2022 Nottingham, UK- 22nd of July 2022- FOR IMMEDIATE RELEASE CHAIN Biotechnology has strengthened its senior management team through the appointment of Dr Matthew Duchars. Matthew is an experienced leader in vaccine development and manufacture with senior management roles […]

June 22, 2022

CHAIN announces a new collaboration with clinical researchers at the University of Oxford to develop superior oral vaccines for infectious diseases Marlow, UK- 22nd of June 2022- FOR IMMEDIATE RELEASE CHAIN Biotechnology and the University of Oxford plan to collaborate on a two-year project to develop a new type of vaccine to immunise against human […]

May 31, 2022

Following successful patent applications in the EU and US, CHAIN have extended their patent territories and claimed delivery of β-hydroxy butyrate (β-HB) to the gastrointestinal (GI) tract in Japan. The patent family (publication number: WO2018055388) ‘Compositions and uses thereof for treating inflammatory diseases and probiotic compositions’ covers genetically engineered bacterial strains to express β-HB in […]

May 7, 2021

 CHAIN has developed a platform technology called CADDTM for oral drug delivery based on living bacteria (known as live biotherapeutics).  CADDTM is unique, transformational with broad clinical applicability. US and EU patents describing the use of CADDTM to treat inflammatory bowel disease have recently been granted. Marlow, UK – 7th May 2021 – FOR IMMEDIATE […]

January 4, 2021

Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Marlow, UK – 4th January 2021 – FOR IMMEDIATE RELEASE CHAIN Biotechnology (CHAIN), a UK-based microbiome therapeutics company, focused on the development of oral vaccines, announced today that Heads of […]

June 22, 2020

Following a 2-month closure, CHAIN reopened its laboratories in Nottingham on the 1st June. This comes after a risk assessment and change to working practices to maintain safe working for staff in the labs and office. MediCity has also implemented new measures in the building to support safe working practices which have also contributed to […]